Amodiaquine

Amodiaquine
Clinical data
Trade namesAmdaquine, Amobin, Camoquin, others[1]
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 4-[(7-chloroquinolin-4-yl)amino]-2-[(diethylamino)methyl]phenol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.001.518 Edit this at Wikidata
Chemical and physical data
FormulaC20H22ClN3O
Molar mass355.87 g·mol−1
3D model (JSmol)
  • Clc1cc2nccc(c2cc1)Nc3cc(c(O)cc3)CN(CC)CC
  • InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23) checkY
  • Key:OVCDSSHSILBFBN-UHFFFAOYSA-N checkY
  (verify)

Amodiaquine (ADQ) is a medication used to treat malaria, including Plasmodium falciparum malaria when uncomplicated.[2][3] It is recommended to be given with artesunate to reduce the risk of resistance.[2] Due to the risk of rare but serious side effects, it is not generally recommended to prevent malaria.[2] Though, the World Health Organization (WHO) in 2013 recommended use for seasonal preventive in children at high risk in combination with sulfadoxine and pyrimethamine.[4]

Amodiaquine is a 4-aminoquinoline compound related to chloroquine.[2] The side effects of amodiaquine are generally minor to moderate and are similar to those of chloroquine.[3] Rarely liver problems or low blood cell levels may occur.[2] When taken in excess headaches, trouble seeing, seizures, and cardiac arrest may occur.[2] The WHO recommends its use for pregnant women during the second and third trimester as well as during lactation, but reports that evidence for use in the first trimester is still insufficient.[5]

Amodiaquine was first made in 1948.[6] It is on the World Health Organization's List of Essential Medicines.[7][8] While not available in the United States,[9] it is widely available in Africa.[2][10]

  1. ^ "Amodiaquine". drugs.com. Archived from the original on 27 November 2016. Retrieved 27 November 2016.
  2. ^ a b c d e f g Nair A, Abrahamsson B, Barends DM, Groot DW, Kopp S, Polli JE, et al. (December 2012). "Biowaiver monographs for immediate release solid oral dosage forms: amodiaquine hydrochloride". Journal of Pharmaceutical Sciences. 101 (12): 4390–4401. doi:10.1002/jps.23312. PMID 22949374.
  3. ^ a b Olliaro P, Mussano P (2003). "Amodiaquine for treating malaria". The Cochrane Database of Systematic Reviews (2): CD000016. doi:10.1002/14651858.CD000016. PMC 6532704. PMID 12804382.
  4. ^ Seasonal malaria chemoprevention with sulfadoxine–pyrimethamine plus amodiaquine in children: a field guide (PDF). Geneva: The World Health Organization. August 2013. ISBN 978-92-4-150473-7.
  5. ^ "WHO Guidelines for malaria". www.who.int. Retrieved 2024-01-22.
  6. ^ Ahmad I, Ahmad T, Usmanghani K (1992). "Amodiaquine hydrochloride". Profiles of Drug Substances, Excipients and Related Methodology. Analytical Profiles of Drug Substances and Excipients. Vol. 21. Academic Press. p. 45. doi:10.1016/S0099-5428(08)60388-3. ISBN 978-0-08-086116-6. Archived from the original on 2017-09-08.
  7. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  8. ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  9. ^ "Amodiaquine". Livertox. Archived from the original on 27 November 2016. Retrieved 27 November 2016.
  10. ^ Centers for Disease Control (CDC) (April 1985). "Revised recommendations for preventing malaria in travelers to areas with chloroquine-resistant Plasmodium falciparum". MMWR. Morbidity and Mortality Weekly Report. 34 (14): 185–90, 195. PMID 3156271.

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search